Maravai Lifesciences Holdings, Inc. · NASDAQ:MRVI

Maravai Lifesciences — Q2 2026 Earnings Presentation

26 slides from Maravai Lifesciences's earnings presentation, Aug 6, 2026

  1. Slide 1: Q2 2026 Financial Results

    NASDAQ: MRVI Q2 2026 Financial Results August 6, 2026

  2. Slide 2: Agenda

    Agenda 01 Welcome Deb Hart, Head of Investor Relations 02 Business Highlights Bernd Brust, Chief Executive Officer 03 Financial Results Raj Asarpota, Chief Financial Officer & Guidance 04 Q&A Session Bernd Brust, Chief Executive Officer Raj Asarpota, Chief Financial Officer Chanfeng Zhao, Chief Scie

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation contains, and our officers and representatives may, from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements

  4. Slide 4: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures This presentation presents certain "non-GAAP Measures" as defined by the rules of the Securities and Exchange Commission (the "SEC") as a supplement to results presented in accordance with accounting principles generally accepted in the United States of America ("G

  5. Slide 5: Business Highlights

    Q2 2026 Business Highlights Bernd Brust Chief Executive Officer 5 © 2026 Maravai LifeSciences

  6. Slide 6: Q2 financial highlights

    Q2 financial highlights TriLink +12% YoY driven by GMP and mRNA Discovery Q2 ADJUSTED Q2 ADJUSTED Cygnus +3% YoY; fifth Q2 REVENUE GROSS MARGIN1 EBITDA1 consecutive quarter of $51.4 M 58.9% $8.7 M revenue growth +9% +1,600bps $19.1 million improvement in Adjusted EBITDA YoY 1. Reconciliation provide

  7. Slide 7: Our strategy is driving improved results

    Our strategy is driving improved results Commercial Operational Innovation Execution Excellence • GMP enzymes launched in Q2 • Better forecasting, improved • Restructuring substantially • ModTail traction with 125 + visibility and stronger order complete customers and demand for conversion • Q2 Debt

  8. Slide 8: Two reporting segments, Cygnus and TriLink; different growth dynamics

    Two reporting segments, Cygnus and TriLink; different growth dynamics ~68% of revenue* TriLink diversified genetic-medicine platform HSD ex commercial/LDD incl. commercial % of Revenue* 5-year Expected Growth Rate mRNA Discovery, GMP, and Commercial >40% HSD/LDD CDMO End-to-end contract manufacturin

  9. Slide 9: Financial Results

    Q2 2026 Financial Results Raj Asarpota Chief Financial Officer 9 © 2026 Maravai LifeSciences

  10. Slide 10: Q2 2026 Results

    Q2 2026 Results Business Segment Customer Mix Geographical Mix • BioPharma: 30% • NA: 62% • TriLink revenue of $34.7 M • Life Sciences & Diagnostics: 35% • EMEA: 20% • Cygnus revenue of $16.8 M • Academia: 5% • Asia Pacific: 11% • CRO/CMO/CDMO: 7% • China: 7% • Distributor: 23% 10 ©2026 Maravai Life

  11. Slide 11: Q2 financial overview

    Q2 financial overview GAAP Net Loss of $21.6 M1 Earnings Per Share ($)3,4,5 ($48.2 M improvement YoY) Basic EPS Diluted EPS Adjusted EPS ($0.05) ($0.05) Adjusted EBITDA of ($0.08) ($0.08) ($0.02) $8.7 M2 (>$19.1 M improvement YoY) 1. GAAP net loss prior to amounts attributable to non-controlling int

  12. Slide 12: Balance Sheet and other financial metrics

    Balance Sheet and other financial metrics Cash Debt Net Cash1 $70.1 M $147.1 M ($77.0) M Fully Diluted Net Interest Stock-based Shares Expense Compensation Outstanding2 $3.7 M $10.2 M 267.4 M 1. Based on Cash less long-term debt 2. The fully diluted share count impacting our Adjusted EPS metrics was

  13. Slide 13: Q2 business segment financials

    Q2 business segment financials Revenue Cygnus TriLink $16.8 M +3% • 67% of total Maravai revenue • $7.0 M of Adjusted EBITDA1,2 • 20% Adjusted EBITDA margin Cygnus TriLink $34.7 M • 33% of total Maravai revenue +12% • $11.4 M of Adjusted EBITDA1,2 • 68% Adjusted EBITDA margin 1. Reconciliation provi

  14. Slide 14: Updated 2026 guidance

    Updated 2026 guidance Prior Guidance Updated Guidance REVENUE $205 to $215 million No change ADJUSTED EBITDA $30 to $32 million $33 to $35 million Updated guidance reflects expectations for gross margin expansion and higher-confidence in expected profitability 14 ©2026 Maravai LifeSciences.

  15. Slide 15: Q&A

    Q&A Bernd Brust, Chief Executive Officer Raj Asarpota, Chief Financial Officer Chanfeng Zhao, Chief Scientific Officer 15 © 2026 Maravai LifeSciences

  16. Slide 16: Closing Commentary

    Closing Commentary Bernd Brust Chief Executive Officer 16 © 2026 Maravai LifeSciences

  17. Slide 17: Seeing meaningful financial progress

    Seeing meaningful financial progress Strong first half of the year with building momentum TriLink is driving growth; Cygnus remains stable high-margin contributor Structural improvements are translating to results Operational leverage expected to drive sustained performance 17 ©2026 Maravai LifeScie

  18. Slide 18: Thank you

    Thank you 18 ©2026 Maravai LifeSciences.

  19. Slide 19: Appendix for forward-looking statements and non-GAAP measures

    Appendix for forward-looking statements and non-GAAP measures 19 ©2026 Maravai LifeSciences.

  20. Slide 20: Forward-Looking Statements — Important Factors

    Forward-Looking Statements — Important Factors Important factors that could cause actual results to differ materially from our forward-looking statements include, among others: • Customer spending on and demand for TriLink and Cygnus products and services, and dependency on a limited number of custo

  21. Slide 21: Non-GAAP reconciliations

    Non-GAAP reconciliations This presentation contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted fully diluted Earnings Per Share

  22. Slide 22: Net Loss to Adjusted EBITDA (Non-GAAP)

    Net Loss to Adjusted EBITDA (Non-GAAP) (in thousands, except per share amounts) 22 ©2026 Maravai LifeSciences.

  23. Slide 23: Net Loss to Adjusted Net Income (Loss) and Adjusted Fully Diluted EPS

    Net Loss attributable to Maravai LifeSciences Holdings, Inc. to Adjusted Net Income (Loss) (non- GAAP) and Adjusted Fully Diluted Earnings (Loss) Per Share (non-GAAP) 23 ©2026 Maravai LifeSciences.

  24. Slide 24: Explanatory Notes to Reconciliations

    Explanatory Notes to Reconciliations (1) Refers to incremental costs incurred to execute and integrate completed acquisitions, including retention payments related to integration that were negotiated specifically at the time of the Company’s acquisition of Alphazyme, which was completed in January 2

  25. Slide 25: Reconciliation of Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP)

    Reconciliation of Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) (in thousands) 25 ©2026 Maravai LifeSciences.

  26. Slide 26: Adjusted EBITDA by Segment

    Adjusted EBITDA by Segment (in thousands) Explanatory Notes: (1) Expenses are adjusted to remove the impact of certain items, including interest, taxes, depreciation and amortization, certain non-cash items and other adjustments. Management believes these do not directly reflect our core operations,

Maravai LifeSciences Holdings — Q2 2026 Earnings Presentation on 6ix